Cox multivariate analysis revealed that CD47 expression and clinical staging are independent risk factors for prognosis, suggesting that reducing CD47 expression could enhance immune response, inhibit tumor cell proliferation, and potentially serve as a specific therapeutic approach for NSCLC. Here, CD47 is linked to neoplasm.